Provided by Tiger Trade Technology Pte. Ltd.

Royalty Pharma plc

58.75
-1.8400-3.04%
Pre-market: 58.26-0.4900-0.83%04:31 EDT
Volume:3.32M
Turnover:197.27M
Market Cap:33.90B
PE:31.51
High:60.71
Open:60.45
Low:58.64
Close:60.59
52wk High:64.38
52wk Low:34.63
Shares:576.94M
Float Shares:392.53M
Volume Ratio:0.75
T/O Rate:0.85%
Dividend:0.91
Dividend Rate:1.55%
EPS(TTM):1.86
EPS(LYR):1.78
ROE:13.97%
ROA:5.09%
PB:4.96
PE(LYR):32.98

Loading ...

BRAIN Biotech Receives EUR 11.51 Million Milestone Payment from Royalty Pharma

Reuters
·
Sep 09

Analysts Conflicted on These Healthcare Names: Amgen (AMGN), Beam Therapeutics (BEAM) and Royalty Pharma (RPRX)

TIPRANKS
·
Sep 09

U.S. Stocks on the MOVE-Best Buy, Peloton, Apple

Reuters
·
Sep 09

Royalty Pharma Down Nearly 6%, on Pace for Largest Percent Decrease Since March 2025

Dow Jones
·
Sep 09

Royalty Pharma Falls After Novartis' Cholesterol Drug Fails in Study

Reuters
·
Sep 09

Movement Alert|Royalty Pharma plc Falls 6.4% in Regular Trading, S&P 500 Index Inclusion Expectation Missed Triggering Selloff

Market Focus
·
Sep 09

Movement Alert|Royalty Pharma plc Falls 5.72% in Pre-Market Trading, S&P 500 Index Quarterly Rebalancing Inclusion Expectation Unmet

Market Focus
·
Sep 08

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Royalty Pharma (RPRX) and Summit Therapeutics (SMMT)

TIPRANKS
·
Sep 08

Royalty Pharma Announces Update on Novartis’ Phase 3 Topline Results for Pelacarsen

THOMSON REUTERS
·
Sep 05

Royalty Pharma - Expects to Recoup Investment and Earn Modest Return Despite Pelacarsen Failure

THOMSON REUTERS
·
Sep 05

Zenas BioPharma Highlights FDA Review Acceptance for Obexelimab IgG4-RD Filing in Corporate Presentation

Reuters
·
Aug 31

Royalty Pharma EVP and Chairman of Partnering Christopher Hite Sells 100,000 Shares for $6 Million

Reuters
·
Aug 20

Royalty Pharma CFO Terrance P. Coyne Sells USD 645,248 in Common Shares

Reuters
·
Aug 18

Royalty Pharma and Zealand Pharma Enter into Rusfertide Funding Agreement for $100 Million

THOMSON REUTERS
·
Aug 13

Zealand Pharma Sells Rusfertide Royalty Interests to Royalty Pharma for USD 100 Million

Reuters
·
Aug 13

Royalty Pharma Publishes Transcript of Q2 2026 Financial Results Call

Reuters
·
Aug 11

J.P. Morgan Keeps Their Buy Rating on Royalty Pharma (RPRX)

TIPRANKS
·
Aug 11

Canada's DRI Healthcare Q2 Income Rises, Helped by Milestone Events in Royalty Portfolio

Reuters
·
Aug 08

Xenetic Biosciences Q2 Royalty Revenue Rises on Takeda Sublicense

Reuters
·
Aug 07

Halozyme Q2 Revenue Jumps 48%, Raises 2026 Outlook

Reuters
·
Aug 07